Bioretec appoints Rami Ojala as Sales and Marketing Director and member of the Management Team

Ojala will succeed Lauri Hokkanen, Bioretec’s current Sales and Marketing Director and member of the Management Team, who has decided to pursue new career opportunities outside the company. Hokkanen will continue in Bioretec’s employ until 31 January 2022, familiarizing his successor to the new role.

Rami Ojala has close to 15 years of experience from medical device sales and marketing. He joins Bioretec from Impulse Dynamics GmbH, where he has worked as Regional and Country Manager, Finland & Baltics since 2017, responsible for sales and marketing activities, launching a new therapy for symptomatic heart failure, distributor management as well as customer training and education. Prior to this, he held various sales and marketing positions for Medtronic’s medical device portfolio and worked as sales representative for Oriola-KD Healthcare.

”We are delighted to have Rami Ojala strengthen Bioretec’s Management Team and lead the company’s sales and marketing operations.  Bioretec's vision is to become a globally recognized medical device company and a leader in bioresorbable metal implants. Rami will play a significant role in executing our growth strategy through driving sales and finding new growth avenues. His comprehensive competence and international experience from medical devices, launching new products and therapies, opening new geographical markets and working with distributors will meet our needs perfectly and support our growth journey. I would also like to warmly thank Lauri Hokkanen for his contribution in Bioretec's sales and marketing activities and wish him all the best for the future," says Timo Lehtonen, Chief Executive Officer of Bioretec.

Timo Lehtonen, CEO, tel. +358 50 433 8493
Johanna Salko, CFO, tel. +358 40 754 8172

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery.   The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. With the U.S. and EU market authorization for the first RemeOs™ product expected in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities. Better Healing – Better Life. www.bioretec.com.